Infliximab in moderate to severe ulcerative colitis: comparison between scheduled treatment strategy and bridge strategy

被引：0
|
作者：
Sambuelli, A. [1 ]
Bellicoso, M. [1 ]
Negreira, S. [1 ]
Goncalves, S. [1 ]
Huernos, S. [1 ]
Chavero, P. [1 ]
Tirado, P. [1 ]
Cabanne, A. [2 ]
Gil, A. [1 ]
机构：
[1] Hosp Bonorino Udaondo, IBD Sect, Med, Buenos Aires, DF, Argentina
[2] Hosp Bonorino Udaondo, Dept Pathol, Buenos Aires, DF, Argentina
来源：
JOURNAL OF CROHNS & COLITIS | 2017年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P585
引用
收藏
页码：S378 / S379
页数：2
相关论文
共 50 条
  • [31] COMPARATIVE EFFICACY AND SAFETY OF GOLIMUMAB, INFLIXIMAB AND ADALIMUMAB FOR THE TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS: A BAYESIAN INDIRECT TREATMENT COMPARISON META-ANALYSIS
    Thorlund, K.
    Druyts, E.
    Eapen, S.
    Mills, E.
    VALUE IN HEALTH, 2014, 17 (03) : A35 - A35
  • [32] Infliximab for the treatment of ulcerative colitis
    Hyde, C.
    Bryan, S.
    Juarez-Garcia, A.
    Andronis, L.
    Fry-Smith, A.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 7 - 11
  • [33] Comparison of accelerated infliximab induction versus standard induction treatment in acute severe ulcerative colitis
    Choy, M.
    Seah, D.
    Gorelik, A.
    Macrae, F.
    Sparrow, M.
    Connell, W. R.
    Moore, G.
    Van Langenberg, D.
    De Cruz, P.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S252 - S252
  • [34] Comparison of Accelerated Infliximab Induction vs Standard Induction Treatment in Acute Severe Ulcerative Colitis
    Choy, Matthew C.
    Seah, Dean
    Gorelik, Alexandra
    Macrae, Finlay A.
    Sparrow, Miles
    Connell, William
    Moore, Gregory T.
    De Cruz, Peter
    GASTROENTEROLOGY, 2016, 150 (04) : S803 - S803
  • [35] Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis
    Jiang, Xue-Liang
    Cui, Hui-Fei
    Gao, Jing
    Fan, Hua
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2015, 49 (07) : 582 - 588
  • [36] The efficacy of initial treatment with infliximab without previous conventional therapy in patients with moderate-to-severe ulcerative colitis
    Prymak, O.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S280 - S280
  • [37] Cost-effectiveness analysis of infliximab versus CinnoRA in the treatment of moderate to severe ulcerative colitis in Iranian patients
    Olfatifar, Meysam
    Aghdaei, Hamid Asadzadeh
    Dehkordi, Ayda Hasanpour
    Shahrokh, Shabnam
    Pourhoseingholi, Mohamad Amin
    Balaii, Hedieh
    Rajabnia, Mohsen
    Ivanchuk, Maria
    Ivanchuk, Pavlo
    Nazari, Saeed Hashemi
    Sabour, Siamak
    Rohani, Pejman
    Mehralian, Gholamhossein
    Khodakarim, Soheila
    Hatami, Behzad
    Malekpour, Habib
    Sherkat, Ghazal
    Zali, Mohammad Reza
    Pordanjani, Sajjad Rahimi
    IMMUNOPATHOLOGIA PERSA, 2023, 9 (02):
  • [38] Improvement in Patient Quality of Life during Treatment with Infliximab, Azathioprine, or Combination Infliximab plus Azathioprine for Moderate-to-severe Ulcerative Colitis
    Panaccione, PosterRemo
    Ghosh, Subrata
    Middleton, Stephen
    Marquez, Juan
    Flint, Laurence
    van Hoogstraten, Hubert J.
    Chen, Annie
    Zheng, Hanzhe
    Danese, Silvio
    Rutgeerts, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S544 - S545
  • [39] The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis
    Bressler, B.
    Law, J. K.
    Sheraisher, N. Al Nahdo
    Atkinson, K.
    Byrne, M. F.
    Chung, H. V.
    Fishman, M.
    Partovi, N.
    Pearson, D.
    Penner, R.
    Enns, R. A.
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 22 (11): : 937 - 940
  • [40] 'Treat to Target' in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy
    Dal Buono, Arianna
    Roda, Giulia
    Argollo, Marjorie
    Paridaens, Kristine
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    CURRENT DRUG TARGETS, 2021, 22 (01) : 117 - 125
12345